Opus Point Partners Management Lowers stake in Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) : Opus Point Partners Management reduced its stake in Nektar Therapeutics by 17.33% during the most recent quarter end. The investment management company now holds a total of 288,158 shares of Nektar Therapeutics which is valued at $4,944,791 after selling 60,425 shares in Nektar Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Nektar Therapeutics makes up approximately 4.13% of Opus Point Partners Management’s portfolio.

Other Hedge Funds, Including , Bessemer Group Inc reduced its stake in NKTR by selling 5,519 shares or 99.0% in the most recent quarter. The Hedge Fund company now holds 56 shares of NKTR which is valued at $961.Oxford Asset Management boosted its stake in NKTR in the latest quarter, The investment management firm added 73,105 additional shares and now holds a total of 341,794 shares of Nektar Therapeutics which is valued at $5,882,275. Nektar Therapeutics makes up approx 0.23% of Oxford Asset Management’s portfolio. Her Majesty The Queen In Right Of The Province Of Alberta… added NKTR to its portfolio by purchasing 38,690 company shares during the most recent quarter which is valued at $678,236. Nektar Therapeutics makes up approx 0.01% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio.

Nektar Therapeutics opened for trading at $17.85 and hit $18.12 on the upside on Thursday, eventually ending the session at $18.11, with a gain of 1.46% or 0.26 points. The heightened volatility saw the trading volume jump to 11,64,150 shares. Company has a market cap of $2,476 M.

On the company’s financial health, Nektar Therapeutics reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.33. The company had revenue of $32.77 million for the quarter, compared to analysts expectations of $29.36 million. The company’s revenue was up 44.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.